Table_3_Development and Validation of a Nomogram and a Comprehensive Prognostic Analysis of an LncRNA-Associated Competitive Endogenous RNA Network Based on Immune-Related Genes for Locally Advanced Rectal Cancer With Neoadjuvant Therapy.xlsx

Colorectal cancer (CRC) is a common digestive tract tumor worldwide. In recent years, neoadjuvant chemoradiotherapy (CRT) has been the most comprehensive treatment for locally advanced rectal cancer (LARC). In this study, we explored immune infiltration in rectal cancer (RC) and identified immune-related differentially expressed genes (IRDEGs). Then, we identified response markers in datasets in GEO databases by principal component analysis (PCA). We also utilized three GEO datasets to identify the up- and downregulated response-related genes simultaneously and then identified genes shared between the PCA markers and three GEO datasets. Based on the hub IRDEGs, we identified target mRNAs and constructed a ceRNA network. Based on the ceRNA network, we explored prognostic biomarkers to develop a prognostic model for RC through Cox regression. We utilized the specimen to validate the expression of the two biomarkers. We also utilized LASSO regression to screen hub IRDEGs and built a nomogram to predict the response of LARC patients to CRT. All of the results show that the nomogram and prognostic model offer good prognostic value and that the ceRNA network can effectively highlight the regulatory relationship. hsa-mir-107 and WDFY3-AS2 may be prognostic biomarkers for RC.

结直肠癌（Colorectal cancer, CRC）是全球高发的消化道肿瘤。近年来，新辅助放化疗（neoadjuvant chemoradiotherapy, CRT）已成为局部晚期直肠癌（locally advanced rectal cancer, LARC）的主流综合治疗方案。本研究围绕直肠癌（rectal cancer, RC）的免疫浸润展开探究，首先鉴定免疫相关差异表达基因（immune-related differentially expressed genes, IRDEGs）；随后借助GEO数据库中的数据集，通过主成分分析（principal component analysis, PCA）筛选应答相关标记物；同时利用3个GEO数据集同步鉴定上调及下调的应答相关基因，并获取主成分分析标记物与3个GEO数据集的交集基因。基于核心免疫相关差异表达基因，我们筛选出靶mRNA并构建内源竞争RNA（competing endogenous RNA, ceRNA）网络；以此为基础挖掘预后生物标志物，通过Cox回归构建直肠癌预后模型，并利用临床标本验证其中2个生物标志物的表达水平。此外，我们采用套索回归（LASSO regression）筛选核心免疫相关差异表达基因，构建列线图以预测局部晚期直肠癌患者对新辅助放化疗的应答效果。本研究所有结果均表明，该列线图与预后模型均具备良好的预后评估价值，且内源竞争RNA网络可有效揭示调控关系；其中hsa-mir-107与WDFY3-AS2或可作为直肠癌的预后生物标志物。